The European Commission (EC) has approved a new under-the-skin (subcutaneous), fixed-dose formulation of Janssen’s Darzalex (daratumumab) for the treatment of adults with multiple myeloma. The approval of the new type of delivery applies to all indications for which the therapy’s original intravenous (into-the-vein) formulation is currently approved. That includes its use with newly diagnosed patients and those who have received prior lines of therapy. This also means that people currently receiving intravenous Darzalex may now…
You must be logged in to read/download the full post.
The post New Under-the-skin Darzalex Formulation Approved in EU appeared first on BioNewsFeeds.